Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thejaswini Gopalappa"'
Autor:
Steven M. Bray, Jeeyun Lee, Seung Tae Kim, Joon Young Hur, Philip J. Ebert, John N. Calley, Isabella H. Wulur, Thejaswini Gopalappa, Swee Seong Wong, Hui-Rong Qian, Jason C. Ting, Jiangang Liu, Melinda D. Willard, Ruslan D. Novosiadly, Young Suk Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Amit Aggarwal, Hee Cheol Kim, Christoph Reinhard
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Abstract Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in
Externí odkaz:
https://doaj.org/article/f456fa8deb9947ea89d5b6e8de43eb83
Autor:
Thejaswini Gopalappa, Joon Young Hur, John N. Calley, Isabella H. Wulur, Jeeyun Lee, Philip J. Ebert, Steven M. Bray, Ruslan D. Novosiadly, Jiangang Liu, Melinda D. Willard, Seung Tae Kim, Amit Aggarwal, Young Suk Park, Swee Seong Wong, Hui Rong Qian, Joon Oh Park, Ho Yeong Lim, Hee Cheol Kim, Won Ki Kang, Christoph Reinhard, Jason C. Ting
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-13 (2019)
Anti-EGFR antibodies are effective in therapies for late-stage colorectal cancer (CRC); however, many tumours are unresponsive or develop resistance. We performed genomic analysis of intrinsic and acquired resistance to anti-EGFR therapy in prospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de14fcfac08a919f8125f92abff8b706
https://pubmed.ncbi.nlm.nih.gov/31653970
https://pubmed.ncbi.nlm.nih.gov/31653970
Autor:
Joon Young Hur, Hui-Rong Qian, Philip J. Ebert, Sun Young Kim, Hee Cheol Kim, Ruslan D. Novosiadly, Steven M. Bray, Christoph Reinhard, Jiangang Liu, Thejaswini Gopalappa, Isabella H. Wulur, Amit Aggarwal, Won Ki Kang, Jason C. Ting, Seung Tae Kim, Jeeyun Lee, Melinda D. Willard, John N. Calley, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Swee Seong Wong
Publikováno v:
SSRN Electronic Journal.
Background: Anti-EGFR antibodies are effective therapies for many late-stage colorectal cancer (CRC) patients; however, many tumors are unresponsive or develop resistance. Methods: We performed whole exome sequencing and RNA sequencing of 25 CRC pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::653a4924c079ece3cac8d6031ead691c
https://doi.org/10.2139/ssrn.3307683
https://doi.org/10.2139/ssrn.3307683
Autor:
Jason C. Ting, Thejaswini Gopalappa, John N. Calley, Hui-Rong Qian, Ruslan D. Novosiadly, Christoph Reinhard, Melinda D. Willard, Philip J. Ebert, Jeeyun Lee, Swee Seong Wong, Jiangang Liu, Isabella H. Wulur, Seung Tae Kim, Amit Aggarwal, Hee Cheol Kim, Steven M. Bray
Publikováno v:
Cancer Research. 77:4104-4104
Anti-EGFR antibodies, such as cetuximab, are effective therapies for many late-stage colorectal cancer (CRC) patients; unfortunately, many tumors are initially unresponsive while others show initial efficacy but eventually develop acquired resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9edf93e3ab900a546bd6f564a1ea70a
https://doi.org/10.1158/1538-7445.am2017-4104
https://doi.org/10.1158/1538-7445.am2017-4104